Valuation: Pluristem Therapeutics Inc.

Market Cap 22.55M 19.32M 18.11M 16.54M 31.21M 2.15B 31.52M 214M 83.14M 1.08B 84.67M 82.83M 3.59B P/E 2024
-1.45x
P/E 2025 -1.39x
Enterprise Value 35.99M 30.84M 28.9M 26.39M 49.81M 3.43B 50.3M 341M 133M 1.73B 135M 132M 5.73B EV / Sales 2024
93.2x
EV / Sales 2025 39.1x
Free-Float
53.43%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 54 2017-03-28
Director of Finance/CFO 42 2022-11-30
Chief Operating Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 54 2015-01-31
Director/Board Member 56 2021-01-05
Director/Board Member 64 2021-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+11.70%-24.18% - - 16.83M
+1.02%+4.95%+3.67%+25.46% 51.21B
-0.29%-2.77%+488.79%+533.74% 45.35B
-0.38%+7.62%+37.39%+17.95% 42.84B
+1.73%+2.28%+22.34%+90.30% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-1.38%+3.20%+30.50%+134.46% 17.31B
+0.01%+1.19% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
+0.37%+6.93%+81.91%+48.97% 14.25B
Average +1.21%+3.06%+86.27%+116.73% 30.75B
Weighted average by Cap. +0.15%+2.89%+104.62%+135.35%

Financials

2024 2025
Net sales 326K 279K 262K 239K 451K 31.08M 456K 3.09M 1.2M 15.68M 1.22M 1.2M 51.93M 1.34M 1.14M 1.07M 980K 1.85M 127M 1.87M 12.65M 4.93M 64.26M 5.02M 4.91M 213M
Net income -20.89M -17.9M -16.77M -15.32M -28.91M -1.99B -29.2M -198M -77.01M -1B -78.43M -76.72M -3.33B -22.58M -19.35M -18.13M -16.56M -31.26M -2.15B -31.57M -214M -83.26M -1.09B -84.79M -82.95M -3.6B
Net Debt -373K -320K -299K -274K -516K -35.56M -521K -3.53M -1.38M -17.94M -1.4M -1.37M -59.41M 13.44M 11.51M 10.79M 9.86M 18.6M 1.28B 18.78M 127M 49.54M 646M 50.45M 49.35M 2.14B
Logo Pluristem Therapeutics Inc.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-